Hemovigilance Unit, Department of Laboratory Medicine, Division of Pathology and Laboratory Medicine; The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lab Med. 2022 Jul 4;53(4):344-348. doi: 10.1093/labmed/lmab119.
Transfusion-associated circulatory overload (TACO) is a largely preventable transfusion complication that results in significant morbidity and mortality. Cancers, related treatments, and comorbidities are among the factors that can predispose patients to TACO, but currently there are limited data on this topic in the literature.
We collected data retrospectively from the electronic health records of 93 adult patients with cancer who met Centers for Disease Control and Prevention (CDC) criteria for TACO from July 1, 2019, through October 31, 2020. The parameters we studied included demographics, comorbidities, treatment modalities, transfusion practices, and outcomes. We summarized data by means and ranges for continuous variables, and proportions for categorical variables.
During the study period, the incidence of TACO among oncology patients was 0.84 per 1000 transfusions (95% CI, 0.68-1.02), representing 6.6% of all reactions. This percentage is high, compared with 1%-6% among other populations. Unique characteristics such as hematology malignancy (75.3%), receipt of cardiotoxic chemotherapy (87.1%), pneumonia (57.0%), preexisting oxygen use (59.1%), dyspnea (62.4%), hypertension (55.9%), renal insufficiency (46.2%), daily use of corticosteroids (43.0%), daily use of diuretics (40.9%), daily use of beta-blockers (36.6%), and elevated NT-proBNP (33.3%) were frequently observed in these group of oncology patients.
Our study indicates that oncology patients have unique factors that may lead to diagnosis of TACO. Developing appropriate guidelines that apply to oncology patients, in addition to those set forth by the CDC, should be considered. Implementation by ordering healthcare providers of a tools that can predict TACO can help in early recognition and mitigation of TACO.
输血相关循环超负荷(TACO)是一种主要可预防的输血并发症,可导致严重的发病率和死亡率。癌症、相关治疗和合并症是导致患者发生 TACO 的因素之一,但目前文献中关于这一主题的数据有限。
我们从 2019 年 7 月 1 日至 2020 年 10 月 31 日期间,通过电子病历回顾性收集了符合疾病预防控制中心(CDC)TACO 标准的 93 例成年癌症患者的数据。我们研究的参数包括人口统计学、合并症、治疗方式、输血实践和结果。我们通过连续变量的平均值和范围以及分类变量的比例来总结数据。
在研究期间,肿瘤患者 TACO 的发生率为每 1000 次输血 0.84 例(95%CI,0.68-1.02),占所有反应的 6.6%。与其他人群的 1%-6%相比,这一比例较高。血液恶性肿瘤(75.3%)、接受心脏毒性化疗(87.1%)、肺炎(57.0%)、预先使用氧气(59.1%)、呼吸困难(62.4%)、高血压(55.9%)、肾功能不全(46.2%)、每日使用皮质类固醇(43.0%)、每日使用利尿剂(40.9%)、每日使用β受体阻滞剂(36.6%)和升高的 NT-proBNP(33.3%)等独特特征在这群肿瘤患者中经常出现。
我们的研究表明,肿瘤患者有独特的因素可能导致 TACO 的诊断。除了 CDC 制定的指南外,还应考虑制定适用于肿瘤患者的适当指南。通过为医疗保健提供者提供可预测 TACO 的工具,促使其实施,有助于早期识别和缓解 TACO。